Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by Wall Street Zen

Inovio Pharmaceuticals (NASDAQ:INO) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

Several other analysts also recently commented on INO. Weiss Ratings raised Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. Finally, HC Wainwright cut their price objective on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a report on Monday, June 1st. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Inovio Pharmaceuticals has an average rating of “Hold” and an average price target of $4.25.

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $1.11 on Friday. The stock has a market cap of $91.73 million, a PE ratio of -0.77 and a beta of 1.49. The stock has a 50-day moving average of $1.20 and a 200-day moving average of $1.55. Inovio Pharmaceuticals has a one year low of $1.03 and a one year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. As a group, research analysts anticipate that Inovio Pharmaceuticals will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently modified their holdings of the stock. Focus Partners Wealth acquired a new position in Inovio Pharmaceuticals in the 3rd quarter valued at about $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 18,160 shares during the period. Raymond James Financial Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 16,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Inovio Pharmaceuticals in the third quarter valued at approximately $41,000. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.